The Priority Review

Tag

Rheumatology

1 story

  1. Business

    Lilly: 43.7 percent reached ACR50 at week 52 on Taltz plus Zepbound vs 15.7 percent on Taltz alone

    Eli Lilly and Company said 43.7 percent of adults with psoriatic arthritis and obesity or overweight reached ACR50 at 52 weeks on Taltz and Zepbound together, against 15.7 percent on Taltz alone. The company gave the figures at ACR Convergence 2026 for the TOGETHER-PsA trial.